fda approves semaglutide weight-loss drug Wegovy to reduce heart-disease risks FDA Approves Oral Semaglutide for

W.BrandmeirN

Store the drug at room temperature below 25 degree centigrade

In other words, these subjects ended up leaner and stronger for their size

The GLP-1 class of drugs has revolutionized the treatment of diabetes and obesity while also reducing cardiovascular adverse events

You wake up

Providing adolescents with obesity another option Wegovy is the only once-weekly injectable GLP-1 RA indicated to reduce excess body weight and maintain weight reduction long term in combination with diet and exercise in adolescents with obesity aged 12 years and older 3 The safety and effectiveness of Wegovy injection have not been established in pediatric patients to reduce the risk of major adverse CV events or to reduce excess body weight and maintain weight reduction long term in those less than 12 years of age